Avanos Medical (NYSE:AVNS) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Avanos Medical (NYSE:AVNS) posted its quarterly earnings data on Tuesday. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.05, FiscalAI reports. The firm had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 EPS. Avanos Medical updated its FY 2026 guidance to 0.900-1.100 EPS.

Here are the key takeaways from Avanos Medical’s conference call:

• Avanos’s Specialty Nutrition Systems outperformed the market, growing over 8% organically in 2025 (short-term feeding up double-digits and neonatal +6%); the Nexus Medical tuck‑in contributed roughly $5M and is expected to be a double‑digit grower in 2026.
• The company expects about $30 million of tariff P&L costs in 2026 (a $12M increase versus 2025), with roughly two‑thirds China‑related, though management plans to exit syringe sourcing from China by June to mitigate future impact.
• 2026 guidance calls for net sales of $700M–$720M, consolidated mid‑single‑digit organic growth (SNS mid‑to‑high singles, PMNR low‑to‑mid singles) and adjusted EPS of $0.90–$1.10, with gross‑margin improvement expected in H2 2026 and into 2027.
• Balance sheet and cash flow remain healthy with $90M cash, $100M debt, leverage well under 1x and FY free cash flow of $43M, while planned 2026 CapEx is ~$25M to support the China‑exit and production moves to Mexico/Southeast Asia.
• Management continues portfolio reshaping and cost discipline—completed the HA divestiture, exited Game Ready rentals, is exiting IV therapy in Q1 2026, and expects ongoing operating efficiencies and targeted M&A to drive margin and growth.

Avanos Medical Price Performance

AVNS traded down $0.01 during midday trading on Thursday, hitting $14.36. The stock had a trading volume of 153,386 shares, compared to its average volume of 579,204. The company has a market cap of $666.36 million, a P/E ratio of -9.11 and a beta of 1.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.15. The business has a fifty day moving average of $12.95 and a 200 day moving average of $12.06. Avanos Medical has a 1 year low of $9.30 and a 1 year high of $15.68.

Analyst Ratings Changes

A number of research analysts have issued reports on AVNS shares. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Finally, Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Institutional Trading of Avanos Medical

Several institutional investors have recently made changes to their positions in AVNS. Russell Investments Group Ltd. boosted its holdings in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in Avanos Medical in the third quarter valued at $70,000. Tower Research Capital LLC TRC grew its stake in Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after buying an additional 5,083 shares during the last quarter. Quantessence Capital LLC acquired a new stake in shares of Avanos Medical in the third quarter valued at approximately $116,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Avanos Medical in the 4th quarter valued at $122,000. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.